Cardiomyopathy: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
Line 108: Line 108:
* {{Cite book|title = Advances in Heart Research and Application: 2013 Edition|last = Acton|first = Q. Ashton|publisher = Scholarly Editions|year = 2013|isbn = 978-1-481-68280-0|location = |pages = }}
* {{Cite book|title = Advances in Heart Research and Application: 2013 Edition|last = Acton|first = Q. Ashton|publisher = Scholarly Editions|year = 2013|isbn = 978-1-481-68280-0|location = |pages = }}
*{{cite journal|last1=Towbin|first1=JA|title=Inherited cardiomyopathies.|journal=Circulation journal : official journal of the Japanese Circulation Society|date=2014|volume=78|issue=10|pages=2347-56|pmid=25186923|url=https://www.ncbi.nlm.nih.gov/pubmed/25186923|accessdate=26 December 2017|issn=1347-4820}}
*{{cite journal|last1=Towbin|first1=JA|title=Inherited cardiomyopathies.|journal=Circulation journal : official journal of the Japanese Circulation Society|date=2014|volume=78|issue=10|pages=2347-56|pmid=25186923|url=https://www.ncbi.nlm.nih.gov/pubmed/25186923|accessdate=26 December 2017|issn=1347-4820}}
*{{cite journal|last1=Maron|first1=Barry J.|last2=Udelson|first2=James E.|last3=Bonow|first3=Robert O.|last4=Nishimura|first4=Rick A.|last5=Ackerman|first5=Michael J.|last6=Estes|first6=N. A. Mark|last7=Cooper|first7=Leslie T.|last8=Link|first8=Mark S.|last9=Maron|first9=Martin S.|title=Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology|journal=Circulation|date=1 December 2015|volume=132|issue=22|pages=e273–280|doi=10.1161/CIR.0000000000000239|url=https://www.ncbi.nlm.nih.gov/pubmed/26621644|accessdate=26 December 2017|issn=1524-4539}}


== External links ==
== External links ==

Revision as of 17:30, 26 December 2017

Cardiomyopathy
Opened left ventricle showing thickening, dilatation, and subendocardial fibrosis noticeable as increased whiteness of the inside of the heart.
SpecialtyCardiology
SymptomsShortness of breath, feeling tired, swelling of the legs[1]
ComplicationsHeart failure, irregular heart beat, sudden cardiac death[2][1]
TypesHypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular dysplasia, takotsubo cardiomyopathy[3]
CausesUnknown, genetic, alcohol, heavy metals, amyloidosis, stress[4][3]
TreatmentDepends on type and symptoms[5]
Frequency2.5 million with myocarditis (2015)[6]
Deaths354,000 with myocarditis (2015)[7]

Cardiomyopathy is a group of diseases that affect the heart muscle.[8] Early on there may be few or no symptoms.[1] Some people may have shortness of breath, feel tired, or have swelling of the legs due to heart failure.[1] An irregular heart beat may occur as well as fainting.[1] Those affected are at an increased risk of sudden cardiac death.[2]

Types of cardiomyopathy include hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular dysplasia, and takotsubo cardiomyopathy (broken heart syndrome).[3] In hypertrophic cardiomyopathy the heart muscle enlarges and thickens.[3] In dilated cardiomyopathy the ventricles enlarge and weaken.[3] In restrictive cardiomyopathy the ventricle stiffens.[3]

The cause is frequently unknown.[4] Hypertrophic cardiomyopathy is often, and dilated cardiomyopathy in a third of cases is inherited from a person's parents.[4] Dilated cardiomyopathy may also result from alcohol, heavy metals, coronary heart disease, cocaine use, and viral infections.[4] Restrictive cardiomyopathy may be caused by amyloidosis, hemochromatosis, and some cancer treatments.[4] Broken heart syndrome is caused by extreme emotional or physical stress.[3]

Treatment depends on the type of cardiomyopathy and the degree of symptoms.[5] Treatments may include lifestyle changes, medications, or surgery.[5] In 2015 cardiomyopathy and myocarditis affected 2.5 million people.[6] Hypertrophic cardiomyopathy affects about 1 in 500 people while dilated cardiomyopathy affects 1 in 2,500.[3][9] They resulted in 354,000 deaths up from 294,000 in 1990.[10][7] Arrhythmogenic right ventricular dysplasia is more common in young people.[2]

Signs and symptoms

Arrhythmia

Symptoms of cardiomyopathies may include fatigue, swelling of the lower extremities and shortness of breath.[11] Further indications of the condtion may include:[11]

Causes

Cardiomyopathies are either confined to the heart or are part of a generalized systemic disorder, both often leading to cardiovascular death or progressive heart failure-related disability. Other diseases that cause heart muscle dysfunction are excluded, such as coronary artery disease, hypertension, or abnormalities of the heart valves.[12] Often, the underlying cause remains unknown, but in many cases the cause may identifiable.[13] Alcoholism, for example, has been identified as a cause of dilated cardiomyopathy, as has drug toxicity, and certain infections (including Hepatitis C). On the other hand, molecular biology and genetics have given rise to the recognition of various genetic causes. For example, mutations in the cardiac desmosomal genes as well as in the DES gene may cause arrhythmogenic right ventricular cardiomyopathy (ARVC).[14][15]

A more clinical categorization of cardiomyopathy as 'hypertrophied', 'dilated', or 'restrictive',[16] has become difficult to maintain because some of the conditions could fulfill more than one of those three categories at any particular stage of their development. The current American Heart Association definition divides cardiomyopathies into primary, which affect the heart alone, and secondary, which are the result of illness affecting other parts of the body. These categories are further broken down into subgroups which incorporate new genetic and molecular biology knowledge.[17]

Mechanism

Symptoms may include shortness of breath after physical exertion, fatigue, and swelling of the feet, legs, or abdomen. Additionally, arrhythmias and chest pain may be present.[11]

The pathophysiology of cardiomyopathies is better understood at the cellular level with advances in molecular techniques. Mutant proteins can disturb cardiac function in the contractile apparatus (or mechanosensitive complexes). Cardiomyocyte alterations and their persistent responses at the cellular level cause changes that are correlated with sudden cardiac death and other cardiac problems.[18]

Diagnosis

Normal sinus rhythm/EKG

Among the diagnostic procedures done to determine a cardiomyopathy are:[11]

Classification

Structural categories of cardiomyopathy
Hypertrophic cardiomyopathy HE stain

Cardiomyopathies can be classified using different criteria:[19]

Treatment

Treatment may include suggestion of lifestyle changes to better manage the condition. Treatment depends on the type of cardiomyopathy and condition of disease, but may include medication (conservative treatment) or iatrogenic/implanted pacemakers for slow heart rates, defibrillators for those prone to fatal heart rhythms, ventricular assist devices (VADs) for severe heart failure, or ablation for recurring dysrhythmias that cannot be eliminated by medication or mechanical cardioversion. The goal of treatment is often symptom relief, and some patients may eventually require a heart transplant.[11]

References

  1. ^ a b c d e "What Are the Signs and Symptoms of Cardiomyopathy?". NHLBI. 22 June 2016. Archived from the original on 15 September 2016. Retrieved 31 August 2016. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  2. ^ a b c "Who Is at Risk for Cardiomyopathy?". NHLBI. 22 June 2016. Archived from the original on 16 August 2016. Retrieved 31 August 2016. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  3. ^ a b c d e f g h "Types of Cardiomyopathy". NHLBI. 22 June 2016. Archived from the original on 28 July 2016. Retrieved 31 August 2016. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  4. ^ a b c d e "What Causes Cardiomyopathy?". NHLBI. 22 June 2016. Archived from the original on 15 September 2016. Retrieved 31 August 2016. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  5. ^ a b c "How Is Cardiomyopathy Treated?". NHLBI. 22 June 2016. Archived from the original on 15 September 2016. Retrieved 31 August 2016. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  6. ^ a b GBD 2015 Disease and Injury Incidence and Prevalence, Collaborators. (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282. {{cite journal}}: |first1= has generic name (help)CS1 maint: numeric names: authors list (link)
  7. ^ a b GBD 2015 Mortality and Causes of Death, Collaborators. (8 October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC 5388903. PMID 27733281. {{cite journal}}: |first1= has generic name (help)CS1 maint: numeric names: authors list (link)
  8. ^ "What Is Sudden Cardiac Arrest?". NHLBI. 22 June 2016. Archived from the original on 28 July 2016. Retrieved 16 August 2016. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  9. ^ Practical Cardiovascular Pathology. Lippincott Williams & Wilkins. 2010. p. 148. ISBN 9781605478418. Archived from the original on 14 September 2016. {{cite book}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  10. ^ GBD 2013 Mortality and Causes of Death, Collaborators (17 December 2014). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385 (9963): 117–71. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442. {{cite journal}}: |first1= has generic name (help)CS1 maint: numeric names: authors list (link)
  11. ^ a b c d e "What Are the Signs and Symptoms of Cardiomyopathy? - NHLBI, NIH". www.nhlbi.nih.gov. Archived from the original on 28 July 2016. Retrieved 25 July 2016. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  12. ^ Lakdawala, NK; Stevenson, LW; Loscalzo, J (2015). "Chapter 287". In Kasper, DL; Fauci, AS; Hauser, SL; Longo, DL; Jameson, JL; Loscalzo, J (eds.). Harrison's Principles of Internal Medicine (19th ed.). McGraw-Hill. p. 1553. ISBN 978-0-07-180215-4.
  13. ^ Pathophysiology of heart disease : a collaborative project of medical students and faculty. Lilly, Leonard S., Harvard Medical School. (5th ed.). Baltimore, MD: Wolters Kluwer/Lippincott Williams & Wilkins. 2011. ISBN 1605477230. OCLC 649701807.{{cite book}}: CS1 maint: others (link)
  14. ^ Klauke B, Kossmann S, Gaertner A, Brand K, Stork I, Brodehl A, Dieding M, Walhorn V, Anselmetti D, Gerdes D, Bohms B, Schulz U, Zu Knyphausen E, Vorgerd M, Gummert J, Milting H (2010). "De novo desmin-mutation N116S is associated with arrhythmogenic right ventricular cardiomyopathy". Hum. Mol. Genet. 19 (23): 4595–607. doi:10.1093/hmg/ddq387. PMID 20829228.
  15. ^ Brodehl A, Hedde PN, Dieding M, Fatima A, Walhorn V, Gayda S, Šarić T, Klauke B, Gummert J, Anselmetti D, Heilemann M, Nienhaus GU, Milting H (2012). "Dual color photoactivation localization microscopy of cardiomyopathy-associated desmin mutants". J. Biol. Chem. 287 (19): 16047–57. doi:10.1074/jbc.M111.313841. PMC 3346104. PMID 22403400.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  16. ^ Valentin Fuster; John Willis Hurst (2004). Hurst's the heart. McGraw-Hill Professional. pp. 1884–. ISBN 978-0-07-143225-2. Archived from the original on 27 May 2013. Retrieved 11 November 2010. {{cite book}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  17. ^ McCartan C, Maso R, Jayasinghe SR, Griffiths LR (2012). "Cardiomyopathy Classification: Ongoing Debate in the Genomics Era". Biochem Res Int. 2012: 796926. doi:10.1155/2012/796926. PMC 3423823. PMID 22924131.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  18. ^ Harvey, Pamela A.; Leinwand, Leslie A. (8 August 2011). "Cellular mechanisms of cardiomyopathy". The Journal of Cell Biology. 194 (3): 355–365. doi:10.1083/jcb.201101100. ISSN 0021-9525. PMC 3153638. PMID 21825071. Archived from the original on 28 September 2016. {{cite journal}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  19. ^ Vinay, Kumar (2013). Robbins Basic Pathology. Elsevier. p. 396. ISBN 978-1-4377-1781-5.
  20. ^ a b Maron, Barry J.; Towbin, Jeffrey A.; Thiene, Gaetano; Antzelevitch, Charles; Corrado, Domenico; Arnett, Donna; Moss, Arthur J.; Seidman, Christine E.; Young, James B. (11 April 2006). "Contemporary Definitions and Classification of the Cardiomyopathies". Circulation. 113 (14): 1807–1816. doi:10.1161/CIRCULATIONAHA.106.174287. ISSN 0009-7322. PMID 16567565. Archived from the original on 20 August 2016. Retrieved 1 August 2016. {{cite journal}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  21. ^ Lipshultz, Steven E.; Messiah, Sarah E.; Miller, Tracie L. (5 April 2012). Pediatric Metabolic Syndrome: Comprehensive Clinical Review and Related Health Issues. Springer Science & Business Media. p. 200. ISBN 9781447123651. Archived from the original on 29 May 2016. {{cite book}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

Further reading

External links